Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
Badar HasanKanwarpreet Singh TandonRafael MiretSikandar KhanAmir RiazAdalberto GonzalezAsad Ur RahmanRoger CharlesNeeraj NarulaFernando J CastroPublished in: Journal of gastroenterology and hepatology (2022)
Use of biologic therapy in IBD patients with a previous history of malignancy was not associated with an increased risk of new or recurrent cancer.